Recce Pharmaceuticals (STU:R9Q) ROCE % : 0.00% (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Recce Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Recce Pharmaceuticals's annualized ROCE % for the quarter that ended in Dec. 2024 was 0.00%.

Recce Pharmaceuticals ROCE % Historical Data

The historical data trend for Recce Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recce Pharmaceuticals ROCE % Chart

Recce Pharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

ROCE %

Get a 7-Day Free Trial

-425.18

-118.09

-73.61

-299.18

Recce Pharmaceuticals Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
ROCE %	Get a 7-Day Free Trial													-305.05	-	-	-	-

Recce Pharmaceuticals ROCE % Calculation

Recce Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2024 )		(A: Jun. 2023 )		(A: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2024 )		(A: Jun. 2023 )		(A: Jun. 2024 )
	=	-10.397	/	( ( (1.583 - 3.004)	+	(3.929 - 9.296) )	/ 2 )
	=	-10.397	/	( (-1.421	+	-5.367)	/ 2 )
	=	-10.397	/	-3.394
	=	306.33 %

Recce Pharmaceuticals's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Jun. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Jun. 2024 )		(Q: Dec. 2024 )
	=	-8.498	/	( ( (3.929 - 9.296)	+	(2.544 - 5.079) )	/ 2 )
	=	-8.498	/	( ( -5.367	+	-2.535 )	/ 2 )
	=	-8.498	/	-3.951
	=	0 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2024) EBIT data.

Recce Pharmaceuticals (STU:R9Q) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Recce Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Recce Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Recce Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Recce Pharmaceuticals Ltd (STU:R9Q) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

RCE:Australia

Address

180 George Street, Level 23, Salesforce Tower, Sydney, NSW, AUS, 2000

Website

https://www.recce.com.au

Recce Pharmaceuticals Ltd is an Australia-based globally-focused biotechnology company engaged in the development and commercialization of a new class of antibiotics. The company operates in only one business segment being research and development of pharmaceutical drugs. The firm operates in three geographic segments being Australia, the United Kingdom, and the United States of America, of which the majority of the revenue comes from Australia. The company offers antibiotic drugs to treat diseases caused by various bacteria namely Sepsis, Neisseria gonorrhoeaei, Escherichia coli, Mycobacterium abscessus, and others.

Recce Pharmaceuticals Headlines

No Headlines